tradingkey.logo
tradingkey.logo
Search

Immix Biopharma Says That 50% Enrollment Has Already Been Surpassed In NEXICART-2

ReutersSep 18, 2025 7:31 PM
facebooktwitterlinkedin

- Immix Biopharma Inc IMMX.O:

  • IMMIX BIOPHARMA ANNOUNCES 50% ENROLLMENT MILESTONE SURPASSED IN ITS ONGOING RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL, NEXICART-2

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI